RVL Pharmaceuticals plc
RVLPQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -6.50% | -9.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.50% | -9.94% | |||
| Cost of Revenue | -15.35% | 1,057.92% | |||
| Gross Profit | -3.38% | -34.98% | |||
| SG&A Expenses | -14.27% | -7.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.35% | 4.81% | |||
| Operating Income | 21.09% | -21.96% | |||
| Income Before Tax | -107.74% | 37.90% | |||
| Income Tax Expenses | -294.83% | 120.35% | |||
| Earnings from Continuing Operations | -105.73% | 36.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -105.73% | 36.61% | |||
| EBIT | 21.09% | -21.96% | |||
| EBITDA | 21.29% | -22.31% | |||
| EPS Basic | -105.65% | 36.71% | |||
| Normalized Basic EPS | 24.35% | -1,464.86% | |||
| EPS Diluted | -105.65% | 36.71% | |||
| Normalized Diluted EPS | 24.35% | -1,464.86% | |||
| Average Basic Shares Outstanding | 0.05% | 0.17% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||